Jump to content

1DD-LSD

From Wikipedia, the free encyclopedia
1DD-LSD
Identifiers
  • (6aR,9R)-N,N-diethyl-6-methyl-4-dodecanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
Chemical and physical data
FormulaC32H47N3O2
Molar mass505.747 g·mol−1
3D model (JSmol)
  • CCCCCCCCCCCC(=O)N1C=C2C[C@@H]3C(=C[C@H](CN3C)C(=O)N(CC)CC)C4=C2C1=CC=C4
  • InChI=1S/C32H47N3O2/c1-5-8-9-10-11-12-13-14-15-19-30(36)35-23-24-21-29-27(26-17-16-18-28(35)31(24)26)20-25(22-33(29)4)32(37)34(6-2)7-3/h16-18,20,23,25,29H,5-15,19,21-22H2,1-4H3/t25-,29-/m1/s1
  • Key:CEPIQEJKLWHRTL-VAVYLYDRSA-N

1DD-LSD (N1-dodecanoyl-lysergic acid diethylamide, SYN-L-004) is an acylated derivative of lysergic acid diethylamide (LSD). In animal studies it produces a weak head-twitch response but with 27x lower potency than LSD itself. It is being researched as a potential slow-onset, long lasting prodrug for LSD which is expected to have reduced psychoactive effects.[1][2]

See also

[edit]

References

[edit]
  1. ^ Kavanagh PV, Westphal F, Pulver B, Elliott SP, Stratford A, Halberstadt AL, Brandt SD (April 2024). "Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)". Drug Testing and Analysis. doi:10.1002/dta.3691. PMID 38569566.
  2. ^ WO 2024028495, Stratford A, Williamson JP, "Prodrugs of Substituted Ergolines", published 8 February 2024, assigned to Synex Holdings BV